<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="328">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330586</url>
  </required_header>
  <id_info>
    <org_study_id>KUMC-COVID-19</org_study_id>
    <nct_id>NCT04330586</nct_id>
  </id_info>
  <brief_title>A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19</brief_title>
  <official_title>A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to In vitro studies, ciclesonide showed good antiviral activity against severe
      acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for
      the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical
      trial to evaluate the antiviral effect on the reduction of viral load in patients with
      COVID-19. In this study, we aimed to investigate whether ciclesonide alone or in combination
      with hydroxychloroquine could eradicate SARS-CoV-2 from respiratory tract earlier in patients
      with mild COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This multicenter study is an open-labelled, randomized clinical trial for 1:1 ratio of ciclesonide or control arm (standard care)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of SARS-CoV-2 eradication at day 14 from study enrollment</measure>
    <time_frame>Hospital day 14</time_frame>
    <description>Viral load</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of SARS-CoV-2 eradication at day 7 from study enrollment</measure>
    <time_frame>Hospital day 7</time_frame>
    <description>Viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to SARS-CoV-2 eradication (days)</measure>
    <time_frame>Hospital day 1, 4, 7, 10, 14, 21</time_frame>
    <description>Viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load area-under-the-curve (AUC) reduction versus control</measure>
    <time_frame>Hospital day 1, 4, 7, 10, 14, 21</time_frame>
    <description>Viral load change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement (days)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Resolution of all systemic and respiratory symptoms for â‰¥2 consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of clinical failure</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>ICU admission, mechanical ventilation or death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and tolerability of study drug</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of adverse events, proportion of early discontinuance</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Ciclesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciclesonide 320ug oral inhalation q12h for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care without ciclesonide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide Metered Dose Inhaler [Alvesco]</intervention_name>
    <description>Ciclesonide 320ug oral inhalation q12h for 14 days</description>
    <arm_group_label>Ciclesonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mild COVID-19 (NEWS scoring system 0-4)

          -  Patient within 7 days from symptom onset or Patient within 48 hous after laboratory
             diagnosis (SARS-CoV-2 RT-PCR)

        Exclusion Criteria:

          -  Hypoxia (SaO2 &lt;95%)

          -  Unable to take oral medication

          -  Unable to use inhaler

          -  Pregnancy or breast feeding

          -  Immunocompromising conditions

          -  Moderate/severe renal dysfunction : creatinine clearance (CCL) &lt; 30 mL/min

          -  Moderate/severe liver dysfunction: AST or ALT &gt; 5 times upper normal limit

          -  Asthma or chronic obstructive lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joon Young Song, MD, PhD</last_name>
    <phone>82-2-2626-3052</phone>
    <email>infection@korea.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Young Song, MD</last_name>
      <phone>82-2-2626-1104</phone>
      <email>infection@korea.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ji Yun Noh, MD</last_name>
      <email>jynoh@korea.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Woo Joo Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Ciclesonide</keyword>
  <keyword>Viral load</keyword>
  <keyword>Coronavirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

